Milak, M S
Proper, C J
Mulhern, S T
Parter, A L
Kegeles, L S
Ogden, R T
Mao, X
Rodriguez, C I
Oquendo, M A
Suckow, R F
Cooper, T B
Keilp, J G
Shungu, D C
Mann, J J
Article History
Received: 10 March 2014
Revised: 29 January 2015
Accepted: 9 March 2015
First Online: 18 August 2015
Competing interests
: Dr Milak, Ms Proper, Ms Mulhern, Ms Parter, Dr Ogden, Dr Keilp, Ms Mao, Mr Cooper, Dr Shungu, Dr Rodriguez and Dr Suckow reported no biomedical financial interests or potential conflicts of interest. Dr Kegeles has received research grants from Pfizer and Amgen. Dr Oquendo receives royalties for use of the Columbia Suicide Severity Rating Scale and received financial compensation from Pfizer for the safety evaluation of a clinical facility, unrelated to this study. She has received unrestricted educational grants and/or lecture fees from Astra-Zeneca, Bristol Myers Squibb, Eli Lilly, Janssen, Otsuko, Pfizer, Sanofi-Aventis and Shire. Her family owns stock in Bristol Myers Squibb. Dr Mann received prior unrelated grants from Novartis and GSK and receives royalties for commercial use of the C-SSRS from the Research Foundation for Mental Health.